Researchers have discovered that bacteria can sense threats in advance through a general danger signal. Bacteria detect when nearby cells are dying and proactively form a protective biofilm.
Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year ...
MRX-8 is under clinical development by MicuRx Pharmaceuticals and currently in Phase I for Acinetobacter Infections. According to GlobalData, Phase I drugs for Acinetobacter Infections does not have ...